ArticleThe British journal of radiology2026
FLASH radiotherapy enables dose escalation resulting in improved survival in an orthotopic muscle-invasive bladder cancer mouse model.
Article in The British journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesFLASH radiotherapy is an innovative technique that delivers radiation at ultra-high dose rates (UHDR), offering tumor control comparable to conventional (CONV) radiotherapy while significantly reducing normal tissue toxicity. Here we aim to determine the effects of FLASH compared to CONV radiotherapy in muscle-invasive bladder cancer (MIBC) models.
methodsUsing an in-house 6 MeV linear accelerator able to deliver electron beam at UHDR or CONV dose rate, we employed clonogenic survival assays, RNA sequencing (RNA-seq), and in vivo tumor growth analyses using MBT2 cells and C3H MIBC models. Both subcutaneous and orthotopic tumor models were used to assess tumor response, survival and treatment-related toxicity as demonstrated by weight loss.
resultsClonogenic analysis demonstrated comparable cancer cell survival between FLASH and CONV irradiation in vitro. RNA-seq analysis of in vitro irradiated cells revealed similar gene expression at 5 Gy but significant transcriptional divergence at 10 Gy. Intestinal organoids exhibited preserved growth after FLASH compared with CONV irradiation, consistent with a normal tissue sparing effect. In subcutaneous models, FLASH and CONV radiotherapy exhibited similar tumor responses. However, in the orthotopic model, FLASH radiotherapy enabled dose escalation, significantly extending survival at 15 Gy (P = .02) and 17.5 Gy (P = .004). Dose rate (100 vs. 106 Gy/s) did not significantly affect survival. The benefit of single-fraction FLASH was not retained with fractionated (3 × 7.3 Gy) delivery.
conclusionsFLASH radiotherapy demonstrates significant potential for treating MIBC, offering enhanced survival through effective dose escalation. These findings support continued investigation into optimal FLASH parameters and its clinical application. ADVANCES IN KNOWLEDGE: This study demonstrates, for the first time, that UHDR radiotherapy enables safe dose escalation and improved survival in an orthotopic muscle-invasive bladder cancer model compared to conventional dose-rate treatment. Survival benefits of FLASH are dose- and fractionation-dependent, with significant improvements observed in single-fraction, high-dose treatments but not in fractionated delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.